Other · developed by Sanofi
SAR444336 is an investigational agent given as a subcutaneous solution for injection. It is being studied in microscopic colitis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07156175 | Phase 2 | Microscopic Colitis | Active not recruiting | SNY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Microscopic Colitis
Updated Nov 1, 2026. Something wrong or missing? Report it on the SNY page.
See SNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SNY catalysts and pipeline →